Patents by Inventor Naoya Tsurushita
Naoya Tsurushita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8952134Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: GrantFiled: September 26, 2012Date of Patent: February 10, 2015Assignee: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Publication number: 20150038682Abstract: The invention provides antibodies or fusion proteins with modified heavy chain IgG constant regions that promote assembly of multimeric complexes. Within an antibody or fusion protein unit there are two heavy chains each including at least CH2 and CH3 regions. The two heavy chains bear complementary modifications (e.g., knob and hole) to promote coupling of the heavy chains within a unit. One and only one of the heavy chains in a unit is fused at its C-terminus to a homomultimerizing peptide. The presence of the homomultimerizing peptide promotes association between units. For example, if the homomultimerizing peptide is a homotrimerizing peptide it promotes association of three units to form a trimeric complex.Type: ApplicationFiled: July 31, 2014Publication date: February 5, 2015Applicant: JN BIOSCIENCES LLCInventors: Naoya Tsurushita, J. Yun Tso
-
Publication number: 20150004178Abstract: Anti-human sema4A antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4A antibodies can inhibit T cell proliferation and Th2 differentiation induced by IL-4, anti-CD3, anti-CD28 and recombinant sema4A.Type: ApplicationFiled: October 5, 2012Publication date: January 1, 2015Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun Liu, Ning Lu, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20140308276Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: February 9, 2012Publication date: October 16, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20140294825Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: ApplicationFiled: April 3, 2014Publication date: October 2, 2014Applicant: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Patent number: 8821863Abstract: The present invention provides humanized antibodies that immunospecifically recognize human ?9 integrin. Some of these antibodies inhibit the biological functions of the ?9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with ?9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: January 13, 2009Date of Patent: September 2, 2014Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon
-
Publication number: 20140193432Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.Type: ApplicationFiled: October 3, 2013Publication date: July 10, 2014Applicant: LIVTECH, INC.Inventors: Koji NAKAMURA, Hiroyuki YANAI, Toru KANKE, Naoya TSURUSHITA, Shankar KUMAR
-
Patent number: 8735552Abstract: The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: March 10, 2010Date of Patent: May 27, 2014Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Tatsuhiro Harada
-
Publication number: 20140037621Abstract: The invention provides constant regions incorporating a cysteine mutation and linked to a ? tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and ? tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.Type: ApplicationFiled: July 31, 2013Publication date: February 6, 2014Applicant: JN Biosciences LLCInventors: Naoya Tsurushita, J. Yun Tso
-
Patent number: 8624007Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: GrantFiled: March 31, 2010Date of Patent: January 7, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Paul R. Hinton, Naoya Tsurushita
-
Patent number: 8617829Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: September 22, 2010Date of Patent: December 31, 2013Assignee: Gene Techno Science Co., Ltd.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita
-
Publication number: 20130344509Abstract: The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.Type: ApplicationFiled: November 20, 2012Publication date: December 26, 2013Inventors: Koji NAKAMURA, Kentaro OKAMURA, Maki TAMURA, Hiroyuki YANAI, Toru KANKE, Naoya TSURUSHITA, Shankar KUMAR
-
Patent number: 8614296Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: April 24, 2009Date of Patent: December 24, 2013Assignee: Gene Techno Science Co., Ltd.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon, Toshimitsu Uede
-
Patent number: 8597647Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.Type: GrantFiled: May 22, 2012Date of Patent: December 3, 2013Assignee: National Cheng Kung UniversityInventors: Ming-Shi Chang, Naoya Tsurushita, Shankar Kumar
-
Publication number: 20130315893Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.Type: ApplicationFiled: May 22, 2012Publication date: November 28, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Ming-Shi CHANG, Naoya Tsurushita, Shankar Kumar
-
Patent number: 8591894Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.Type: GrantFiled: December 22, 2010Date of Patent: November 26, 2013Assignees: Eli Lilly and Company, Washington UniversityInventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
-
Publication number: 20130280275Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: August 23, 2011Publication date: October 24, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20130202618Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: ApplicationFiled: April 15, 2011Publication date: August 8, 2013Applicant: Progenics Pharmaceuticals, Inc.Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Publication number: 20130089547Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: ApplicationFiled: September 26, 2012Publication date: April 11, 2013Applicant: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Publication number: 20120219503Abstract: The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: ApplicationFiled: September 22, 2010Publication date: August 30, 2012Inventors: Shankar Kumar, J. Yen Tso, Naoya Tsurushita